Cart
sales@molnova.com
Dalzanemdor
CAS No. 1629853-48-0
Dalzanemdor( —— )
Catalog No. M35674 CAS No. 1629853-48-0
Dalzanemdor (SAGE-718) is an NMDA receptor-positive modulator of metabolism that can be used to study Huntington's chorea, Alzheimer's disease, and cognitive dysfunction.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 1018 | Get Quote |
|
| 5MG | 1397 | Get Quote |
|
| 10MG | 1881 | Get Quote |
|
| 25MG | 2696 | Get Quote |
|
| 50MG | 3643 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDalzanemdor
-
NoteResearch use only, not for human use.
-
Brief DescriptionDalzanemdor (SAGE-718) is an NMDA receptor-positive modulator of metabolism that can be used to study Huntington's chorea, Alzheimer's disease, and cognitive dysfunction.
-
DescriptionDalzanemdor (SAGE-718) is a N-methyl-D-aspartate (NMDA) receptor positive allosteric modulator.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetiGluR
-
RecptoriGluR | NMDAR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1629853-48-0
-
Formula Weight456.62
-
Molecular FormulaC27H43F3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)[C@@]([C@@H](CC[C@]([C@@](F)(F)F)(C)O)C)(CC4)[H])[H])(CC=C1C[C@@](C)(O)CC2)[H])[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WHO Drug Information. International Nonproprietary Names for Pharmaceutical
molnova catalog
related products
-
Dasolampanel
Dasolampanel (NGX426) is an orally bioavailable, competitive antagonist of the AMPA-kainate receptors for the treatment of chronic pain conditions including neuropathic pain and migraine.
-
TAK-137
TAK-137 is an AMPA receptor enhancer with antidepressant effects. TAK-137 has the ability to improve cognition and could be used to study schizophrenia.
-
Rislenemdaz
A potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively.
